On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.
"Cancer"
-
-
Apparatus
New Findings Confirm: Excellent Data On This Bipotent Antibody Drug Against Ovarian Cancer!
The results of a new study show that Ubamatamab, a bispecific antibody drug, has shown excellent results and a good safety profile in patients with ovarian cancer.
-
Disease
What Is The Difference Between Laryngeal Cancer And Pharyngitis? What Is The Way To Confirm The Diagnosis Of Laryngeal Cancer?
Both laryngeal cancer and laryngitis are common diseases, but there are some differences between these two diseases. Therefore, it is necessary for us to learn more about the common knowledge of laryngeal cancer and laryngitis, which can help us to prevent and detect the diseases.
-
Vocal cord cancer often leads to hoarseness, which is a common symptom of many diseases and can be easily overlooked by patients.
-
Every disease has a cause, and we are all sick because of various factors. Understanding the causes of diseases can help us to prevent them, which will help our health a lot.
-
According to data from cohort 17 of the phase 1b COSMIC-021 trial (NCT03170960), the combination therapy of cabozantinib and atelizumab, at a mean follow-up of 25.9 months, 17% of the 30 patients in cohort 17 had significant tumour shrinkage or disappearance, giving an overall disease control rate of 60% when those with stable lesions were added. 5 patients with tumours in remission All of the patients whose tumours had shrunk by at least 30%.
-
Apparatus
Over 30% Of Tumours In Advanced Lung Cancer Patients In Remission With Frontier Drug Teliso-V In Combination With Troche!
Recently, a study for the treatment of advanced EGFR-mutated and c-MET-positive lung cancer showed good results with the cutting-edge ADC drug teliso-V in combination with the EGFR generation-targeted drug troche (i.e. erlotinib).
-
Apparatus
Acs Med. Chem. Lett.| Protac-Targeted Jak2 Protein Kinase: a New Approach To Cancer Therapy
A new approach to cancer treatment!
-
Apparatus
Cancer Vaccine Shows Its Power! Survival Of Patients With Advanced Colorectal Cancer Extended By More Than 3 Times!
Data from a study of a cancer vaccine combined with a PD-1 immune checkpoint inhibitor has recently been released, and the treatment has increased the survival of patients with advanced colorectal cancer by more than three times, with some patients surviving for more than 22 months so far.
-
Apparatus
Major Breakthrough In 27 Years! This Cancer Vaccine Has Kept Deadly Brain Cancer Patients Alive For Over 8 Years!
A dendritic cell vaccine has shown excellent results in the treatment of glioblastoma, significantly extending the survival of patients with a good safety profile, according to new data from a global clinical trial. To date, patients who have benefited for the longest time have survived for more than eight years.